Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin

@article{Bogdanovich2005AntistaphylococcalAO,
  title={Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin},
  author={T. Bogdanovich and L. Ednie and S. Shapiro and P. Appelbaum},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2005},
  volume={49},
  pages={4210 - 4219}
}
ABSTRACT Ceftobiprole (formerly BAL9141), the active component of the prodrug BAL5788 (ceftobiprole medocaril), is a novel cephalosporin with expanded activity against gram-positive bacteria. Among 152 Staphylococcus aureus isolates, including 5 vancomycin-intermediate and 2 vancomycin-resistant strains, MIC50 and MIC90 values for ceftobiprole were each 0.5 μg/ml against methicillin-susceptible strains and 2 μg/ml against methicillin-resistant strains. Against 151 coagulase-negative… Expand
Antistaphylococcal Activity of Dihydrophthalazine Antifolates, a Family of Novel Antibacterial Drugs
TLDR
Single-step platings of naïve staphylococci onto media containing dihydrophthalazine antifolates indicated considerable variability among strains with respect to preexistent subpopulations nonsusceptible to dihyd phytochemicals, although rates of endogenous resistance development were much lower for the diHydrophthalazines than for trimethoprim. Expand
In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
TLDR
Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested. Expand
Activities of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis
TLDR
Time-kill analyses showed that ceftobiprole, ceftriaxone, cefpodoxime, amoxicillin-clavulanate, azithromycin, telithromyzin, and moxifloxacin were bactericidal at 2× MIC by 24 h against all 10 H. influenzae strains surveyed. Expand
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
TLDR
Ceftobiprole was less active against beta-lactamase-positive Gram-negative bacilli, especially the members of the Bacteroides fragilis group, and piperacillin was active mainly against beta/lactAMase-negative strains, though MIC values for p Piperacillin were often 1 to 2 dilutions higher than for ceftob Piprole. Expand
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
  • M. Jones
  • Medicine, Biology
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2007
TLDR
The broad spectrum of activity demonstrated by ceftobiprole in vitro and in vivo suggests that it may have potential for empirical treatment of suspected Gram-negative and Gram-positive infections, including those caused by MRSA. Expand
CEFTOBIPROLE : FIRST CEPHALOSPORIN WITH ACTIVITY AGAINST MRSA Vidaillac and Rybak Mechanism of Action
Ceftobiprole medocaril is the first member of a new series of advanced cephalosporins with activity against methicillin-resistant Staphylococcus aureus (MRSA). The drug received an approvable letterExpand
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
TLDR
In vitro potency of ceftobiprole is a new anti-MRSA beta-lactam with recognized activity against the most commonly occurring Enterobacteriaceae and P. aeruginosa, similar to that of extended-spectrum cephems, and warrant continued evaluation of the agent as empiric therapy for cSSSIs, and in pneumonia. Expand
Ceftobiprole: First Cephalosporin with Activity Against Methicillin‐Resistant Staphylococcus aureus
TLDR
Ceftobiprole represents a promising option for the treatment of mono‐ and polymicrobial infections caused by multidrug‐resistant gram‐positive and susceptible gram‐negative pathogens, but further toxicity and safety studies are warranted. Expand
Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).
TLDR
Ceftobiprole, a new-generation cephalosporin, is the first beta-lactam agent to demonstrate potent in vitro and in vivo activity against MRSA, and could become the only cep Halosporins with established activity against E. faecalis and MRSA. Expand
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
TLDR
Ceftobiprole, a broad-spectrum cephalosporin with demonstrated in vitro activity against Gram-positive cocci, is a weak inducer and a poor substrate for AmpC beta-lactamases and demonstrates limited activity against anaerobes such as Bacteroides fragilis and non-fragilis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 70 REFERENCES
Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin
TLDR
Prolonged serial passage in the presence of subinhibitory concentrations of ceftobiprole failed to yield mutants with high MICs towards this Staphylococcus aureus cephalosporin, and single-passage selection showed very low frequencies of spontaneous mutants with breakthroughMICs towards ceftOBiprole. Expand
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
TLDR
BAL9141 demonstrated excellent activity against many tested pathogens displaying various resistance phenotypes, and should be particularly valuable in the treatment of MRSA as well as for drug-resistant streptococci, while maintaining a spectrum resembling a 'third-generation' cephalosporin against other clinically important species. Expand
BAL9141, a Novel Extended-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococcus aureus in Treatment of Experimental Endocarditis
TLDR
Promising in vivo results with BAL9141 are correlated with the high affinity of the drug for PBP 2a and its stability to penicillinase hydrolysis observed in vitro. Expand
Newer antistaphylococcal agents
  • J. Bradley
  • Medicine
  • Current opinion in pediatrics
  • 2005
TLDR
The recent worldwide emergence and rapid spread of community-acquired methicillin-resistant S. aureus has prompted a change in the approach to therapy of staphylococcal infections in both the outpatient clinic and the hospital. Expand
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
TLDR
Of the new compounds tested, RP 59500 and sparfloxacin show promise for the treatment of infections caused by penicillin-susceptible and -resistant pneumococci, and at a concentration equal to the MIC it was bactericidal within 3 h. Expand
In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci
TLDR
The potential utility of Ro 63-9141 for the therapy of infections caused by susceptible pathogens, including MRSA, is suggested and a water-soluble prodrug, Ro 65-5788, is considered for development. Expand
Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics.
TLDR
Treatment of staphylococcal infections is made difficult by the increasing emergence of resistance to beta-lactams and other antimicrobials, including reduced susceptibility to glycopeptides. Expand
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.
  • L. Deshpande, R. Jones
  • Biology, Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2003
TLDR
BAL9141 (< or = 8 mg/L) showed promising bactericidal activity alone and synergy with gentamicin against some of the vancomycin-resistant enterococci tested. Expand
Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents
TLDR
Ranbezolid was bacteriostatic against pneumococci and Vancomycin and quinupristin-dalfopristin were also very active, and ranbeZolid MICs for coagulase-negative staphylococci were lower than those for Staphylitis aureus. Expand
Glycopeptide Resistance in Coagulase-Negative Staphylococci
TLDR
In studies of glycopeptide-resistant staphylococci, resistance to teicoplanin was generally easier to obtain than resistance to vancomycin, and the levels of teicountin resistance were higher. Expand
...
1
2
3
4
5
...